ArticleJournal of medicinal chemistry2026

Targeting Multiple KRAS Mutations with High-Affinity Macrocyclic Inhibitors: From Discovery to Preclinical Validation.

Dean P Phillips et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.